Bioreactors Market to be Worth $39.96 Billion by 2031

Bioreactors Market Size, Share, Forecast, & Trends Analysis by Type (Continuous Stirred Tank, Photobioreactor), Bioprocess (Batch, Continuous), Usability (Reusable, Single-use), Scale (Pilot, Industrial), Cell Type, Application, User – Global Forecast to 2031

Meticulous Research^®—a leading market research company, published a research report titled, ‘Bioreactors Market Size, Share, Forecast, & Trends Analysis by Type (Continuous Stirred Tank, Photobioreactor) Bioprocess (Batch, Continuous) Usability (Reusable, Single-use) Scale (Pilot, Industrial) Cell Type, Application, User – Global Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the bioreactors market is projected to reach $39.96 billion by 2031, at a CAGR of 10.1% from 2024 to 2031. The growth of the bioreactors market is driven by several factors, including the capacity expansion of biopharmaceutical plants, the growing pharmaceutical market, rising pharmaceutical R&D expenditures, rising adoption of biosimilars, and growing adoption of single-use technologies in the pharmaceutical and biotechnology industries. Factors such as technological advancements in bioreactor technologies and rising adoption of personalized medicines and cell & gene therapies are opportunities for market growth. Risk of extractables and leachable (E&L) in biomanufacturing processes using single-use bioreactors, process scale-up limitations, the need to standardize single-use bioreactor designs, and environmental concerns related to the disposal of single-use bioreactors challenge the market growth. However, the complex development and manufacturing process of biopharmaceuticals and intensive capital requirements for biopharmaceutical production restrain the growth of the market.

Technological advancements drive the bioreactors market globally. Hybrid bioreactors are systems that involve the introduction of a new phase of attached biomass into a regular suspended growth system by adding carriers into the aeration tanks. These systems offer advantages such as reducing process time, which drives their adoption. Hybrid setups have low installation costs, need less supporting infrastructure, and have a lower environmental impact compared to single-use systems. Production can be scaled up using stainless steel skids in some parts of process development. Thus, the shorter downtimes and lower capital investment requirements of hybrid bioreactors are expected to boost their adoption in the coming years.

Key Players

The key players profiled in the bioreactors market report are Thermo Fisher Scientific, Inc. (U.S.), METTLER TOLEDO (U.S.), Merck KGaA (Germany), Eppendorf AG (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Donaldson Company, Inc. (U.S), BBI-Biotech GmbH (Germany), Infors AG (Switzerland), and Pharsol Ltd. (Slovenia).

The bioreactors market is segmented by Product (Continuous Stirred Tank Bioreactors, Airlift Bioreactors, Fluidized-bed Bioreactors, Packed-bed Bioreactors, Photobioreactors [Open System Photobioreactors, Closed System Bioreactors], Membrane Bioreactors), Bioprocess (Batch/Fed-batch, Continuous), Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, Other Cell Types), Usability (Reusable Bioreactors [Reusable Bioreactors {Stainless Steel, Glass}, Single-use Bioreactors]), Scale (Lab Scale Bioreactors (0.5L-10L), Pilot Scale Bioreactors (10L-200L), Industrial Scale Bioreactors {200L-500L, 500L-1000L, Above 1,500L}]), Automation (Manual, Semi-automated, Automated), Application (Commercial Production [Monoclonal Antibodies (mAb) Production, Cell & Gene Therapy, Vaccine Manufacturing, Plasma Fractionation, Recombinant Protein Production], Development, preclinical & Clinical), End User (Biopharmaceutical Manufacturers, Research & Development Organizations, Contract Manufacturing Organizations) and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.

Among all products, in 2024, the continuous stirred tank bioreactors segment is expected to account for the largest share of the market. The large share of the segment is attributed to factors such as massive volume generation making it an economically viable option, easy temperature control, uniform performance under steady-state conditions, and easy construction of the system as compared to other dedicated flow systems. Several companies are launching products related to bioprocessing and culture production for various industries, justifying its higher adoption. For instance, in March 2020, Erich Stallkamp ESTA GmbH (Germany), a stainless-steel designing, manufacturing, and assembling company, launched its first continuously stirred tank reactors (CSTRs), especially for industrial biogas plants.

Among bioprocesses, in 2024, the batch/fed-batch segment is expected to account for the larger share of the market. Batch processing is carried out when all of the nutrients or reactants are provided to the reactor or the system at the beginning of the cultivation, leading it to be a closed system, therefore, reducing the risk of contamination of the product. Fed-batch is a similar procedure, with the difference that the nutrients or the reactants are added to the container at regular or after specific intervals. The large share of the segment is attributed to factors such as fewer chances of contamination, easy batch material separation, better traceability, and the requirement for fewer volumes of samples.

Among cell types, in 2024, the mammalian cells segment is expected to account for the largest share of the market. Mammalian cells or cell cultures are majorly used for bioproduction owing to certain advantages, such as simplicity in operations, ease of process validation, and higher productivity. The large share of the segment is attributed to factors such as the rising focus on developing complex biomolecules, including monoclonal antibodies and therapeutic proteins, coupled with their ability to perform complex post-translational modifications.

Among usability, in 2024, the reusable bioreactors segment is expected to account for the larger share of the market. Reusable bioreactors are usually made of glass or steel and are mostly used for large scale manufacturing. The large share of the segment is attributed to factors such as low production and operational costs, lower possibility of puncture and damage to the system due to hot reactor liquids, and obtainability of maximum flow rates. The environmental considerations pertaining to the disposal also support the higher demand for reusable bioreactors.

Among scales, the pilot scale bioreactors (10L-200L) segment is slated to register the highest CAGR in the market. The fastest growth of the segment is attributed to factors such as the availability of interchangeable vessels of various sizes, enhanced bioprocessing capabilities, flexible programming, better productivity in cell culture and microbial fermentation, and efficient culture growth. Companies are also investing in advanced technologies such as cloud bioreactors, that can help biopharmaceutical companies to carry out product cultivation without any instruments at their labs. Availability of funding for developing pilot scale bioreactors also supports the higher market share. For instance, in November 2021, Culture Biosciences, Inc. (U.S.) received a USD 80 million Series B round fund, which was led by Northpond Funds (U.S.). This funding round was used to build 5L and 250L pilot-scale cloud bioreactors, supporting the demand for larger quantities of material that was used for tesing and regulatory approval.

Among automation, in 2024, the automated bioreactors segment is expected to account for the larger share of the market. Automated bioreactors are systems that are used for the production of biochemical products. These systems are completely automated and do not require professionals in any step of the procedures. The large share of the market is attributed to factors such as enhanced product quality, cost-savings, and decreased errors.

Among applications, in 2024, the commercial production segment is expected to account for the larger share of the market. The large share of the segment is attributed to factors such as rising demand for biopharmaceuticals, the increasing prevalence of chronic diseases, the increasing number of personalized and targeted therapies, regulatory reforms favoring the adoption of biosimilars, and growing investments and supportive initiatives in developing gene therapies. For instance, the Australian government announced a USD 5 billion, 10-year investment plan for the Medical Research Future Fund (MRFF) as part of the 2019–20 budget. Of this USD 5 billion, USD 150 million is contributed to the mission of stem cell therapies. This would lead to an increased demand for bioreactors, therefore driving the growth of the market. Also, in 2021, Repligen Corporation (U.S.), a life science company involved in biopharmaceutical processing, along with Navigo Proteins GmbH (Germany), a biotechnology company, developed a protein A ligand. This newly developed ligand provides solutions for the problem of antibody aggregation in low pH elution buffers and challenges regarding the Fc-fusion proteins. This ligand helps the affinity purification of monoclonal antibodies in an effective way.

Among end users, in 2024, the biopharmaceutical manufacturers segment is expected to account for the largest share of the market. The large share of the segment is attributed to factors such as increasing demand for biopharmaceutical products, growing incidence & prevalence of various chronic diseases requiring new therapies in the market, and growing focus on developing therapies for rare diseases. Moreover, governments of various countries are taking initiatives by making investments and providing grants & funds to pharmaceutical and biopharmaceutical companies for the manufacture and R&D of biopharmaceuticals. For instance, in 2020, BioNTech SE (Germany), a biotech company, received funding of USD 424 million (EUR 375 million) from the German Federal Ministry of Education and Research to support the development of mRNA-based COVID-19 vaccine. Such investments/funding favorably support the adoption of bioreactors for bioprocessing.

Among geographies, Asia-Pacific is slated to register the highest CAGR of the market. The fast growth of this segment is due to an established pharmaceutical market, increasing R&D expenditures by pharmaceutical and biopharmaceutical companies, and favorable regulatory policies. The number of new Chinese biopharma companies is growing steadily in China. As per the data released by the Chinese president at World Health Assembly 2020, between 2010–2020, over 140 new biotech companies have emerged in China, reaching over 500 biopharmaceutical companies active in the country. To further increase the presence of biopharmaceutical players in China, the government is emphasizing increasing the production capacities of biopharmaceuticals in the country. Such developments are contributing to market growth in Asia-Pacific.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5816

Key questions answered in the report-

Which are the high-growth market segments in terms of bioreactors by product, bioprocess, cell type, usability, scale, automation, application, end user, and geography?
What was the historical market for bioreactors across the globe?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, opportunities, and challenges in the bioreactors market?
Who are the major players operating in the bioreactors market?
What is the competitive landscape like, and who are the leaders in the bioreactors market?
What are the recent developments in the bioreactors market?
What are the different strategies adopted by the major players in the bioreactors market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research